Clinical Research Focus 30th edition | Cromos Pharma

Clinical Research Focus. 30th Edition

Key Takeaways From The 2024 ASCO Annual Meeting

The 2024 ASCO Annual Meeting has once again proven to be a cornerstone event in medical science, showcasing groundbreaking research and clinical advancements that are set to transform cancer treatment and patient care. While it is impossible to cover all the significant research presented at this esteemed forum, this summary highlights a few of the most notable studies that have the potential to affect treatment approaches and improve patient care.

Please follow the link to learn more.

Significant Breakthrough in Epilepsy Treatment with Amber Therapeutics’ Device

In a pioneering UK trial, Amber Therapeutics’ deep brain stimulation device, Picostim DyNeuMo, has dramatically reduced seizures in a teenager with Lennox-Gastaut syndrome by 80%. This first-of-its-kind device, optimized for pediatric use with skull mounting and rechargeable features, offers a new hope in epilepsy management. The CADET pilot study, sponsored by UCL and funded by notable institutions, aims to expand this promising treatment to more patients.

Please follow the link to learn more.

Innovative Oncology Solutions: The Collaborative Success of MAIA Biotechnology and Cromos Pharma

MAIA Biotechnology, Inc. and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate.

Please follow the link to learn more.

Key Insights from the 2024 BIO International Convention

The 2024 BIO International Convention offered groundbreaking insights into biotechnology’s rapid evolution. Alex Card from Definitive Healthcare shares key developments from the event, including advances in AI, gene therapy, and precision medicine, strategies for biotech companies to thrive financially, the challenges of regulatory landscapes, and the potential for global therapy access. 

Please follow the link to learn more.

CEO Insights Podcast: Interview with Vlad Bogin (MD, FACP), Cromos Pharma’s CEO

Vlad Bogin, MD, FACP, CEO Cromos Pharma, recently joined Vitaly Geyman, MBA on the CEO Insights Podcast. In this compelling interview, Vlad delves into the dynamic nature of the pharmaceutical industry, offering his perspectives on managing a global contract research organization. He also explores the latest technological advancements in clinical trials and shares effective strategies for keeping a team motivated and efficient.

Please follow the link to learn more.

NIH’s Combination Therapy Achieves Significant Progress in Treating Resistant B-cell Lymphoma

Researchers at the NIH have developed a combination therapy called ViPOR, demonstrating significant progress in treating aggressive B-cell lymphoma. This non-chemotherapy treatment, tested on patients with lymphoma that resisted standard therapies, achieved complete remission in 38% of cases. The therapy targets multiple pathways, enhancing its effectiveness against specific lymphoma subtypes, particularly non-GCB and double-hit GCB DLBCL.

Please follow the link to learn more.

Digital Twins in Clinical Research: Revolutionizing Study Design

The concept of digital twins, a staple in industries like manufacturing and aerospace, is now making its way into the realm of clinical research. This technology involves creating a virtual replica of a physical entity—in this case, a patient or a biological process—which can then be used to simulate and predict outcomes without direct experimentation.

Please follow the link to learn more.

Enhanced Access to Clinical Trial Information in Europe with Updated CTIS

The European Medicines Agency has launched a new version of the Clinical Trials Information System (CTIS), implementing revised transparency rules that significantly improve access to clinical trial information across the European Union. These changes ensure earlier availability of data on authorized clinical trials, eliminating previous delays in data publication to protect commercial interests. With the updated CTIS, around 4,000 clinical trials are now accessible, with additional features planned to enhance user experience. 

Please follow the link to learn more.

FDA’s Comprehensive New Guidelines Impacting Clinical Trials and Gene Therapy

The FDA has released a significant update affecting several areas, including modified plants, animals, microorganisms, human drugs, biologics, medical devices, and cross-cutting issues. They have developed a comprehensive plan to streamline and clarify regulations and oversight for biotechnology products.

Please follow the link to learn more.

Gilead’s Lenacapavir Shows Promise in HIV Prevention

Gilead Sciences has achieved a groundbreaking milestone in HIV prevention with its twice-yearly injectable Lenacapavir, demonstrating 100% efficacy in the Phase III PURPOSE 1 trial. This first-of-its-kind study marked a zero-infection rate among participants, showcasing superior efficacy compared to daily oral Truvada. The trial’s promising results suggest that Lenacapavir could be a significant advancement in reducing HIV transmission, especially in regions with high rates of the virus.

Please follow the link to learn more.



To arrange an introductory meeting and find out how our experience can benefit your next clinical project.